DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dnvlgb/investigation) has announced the addition of the "Investigation Report on China's Cinepazide Market, 2010-2019" report to their offering.
As a new generation of piperazine, cinepazide (cinepazide maleate) has been widely used in Europe and Japan. As a calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cells and relax smooth muscles of cerebral vessels, coronary arteries and peripheral vessels so as to relieve vasospasm, reduce vascular resistance, improve flexibility of red blood cells, increase blood circulation in cerebral vessels and improve microcirculation and brain metabolism. Cinepazide could also increase the number of cAMP by inhibiting cAMP phosphodiesterase and reduce oxygen consumption.
In April 2002, cinepazide of Beijing Hwellso Pharmaceutical Co., Ltd was approved to enter the market with two dosage forms of oral formulation and injection under the trade name of Kelinao. Currently, Kelinao is the only domestic brand for the treatment of cardiovascular diseases. And in 2009, cinepazide was included in the national medicare drug list.
Cinepazide maleate, after wide application, has gained the recognition of Chinese doctors and patients for the treatment of cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, cerebral hemorrhage sequel and post-traumatic brain syndrome. Besides, due to its efficacy in cardiovascular diseases and peripheral vascular diseases, cinepazide maleate has become a leading product in cerebrovascular drug market. With ageing population, the number of cerebrovascular cases has kept rising, leading to a vast market for cinepazide.
According to this market survey, the annual sales value of cinepazide in sample hospitals has remained over CNY 400 million. Currently, cinepazide market in China is dominated by Beijing Hwellso Pharmaceutical Co., Ltd.
Key Topics Covered:
1 Related Concepts of Cinepazide
2 Market Profile of Cinepazide in China
3 Survey on Cinepazide Sales in China, 2010-2014
4 Survey on Market Share of Major Cinepazide Manufacturers in China, 2010-2014
5 Survey on Dosage Forms of Cinepazide in China, 2010-2014
6 Reference Price of Cinepazide in Chinese Hospitals in 2014
7 Major Manufacturers of Cinepazide in Chinese Market, 2010-2014
8 Market Outlook of Cinepazide in China, 2015-2019
Companies Mentioned
- Beijing Hwellso
- Beijing Hwellso Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/dnvlgb/investigation
